

Claims

1. A substantially pure TIAP polypeptide, said TIAP polypeptide being substantially identical to human TIAP (SEQ ID NO: 2) and having TIAP biological activity.

5 2. The substantially pure TIAP polypeptide of claim 1, wherein said TIAP polypeptide has 85% sequence identity to SEQ ID NO: 2.

3. The substantially pure TIAP polypeptide of claim 2, wherein said TIAP polypeptide has 90% sequence identity to SEQ ID NO: 2.

10 4. The substantially pure TIAP polypeptide of claim 3, said TIAP polypeptide has the sequence of SEQ ID NO: 2.

5. A method for identifying a compound that modulates TIAP biological activity, said method comprising the steps of:

(a) providing a TIAP polypeptide substantially identical to human TIAP (SEQ ID NO: 2);

15 (b) contacting said TIAP polypeptide with a candidate compound; and

(c) determining the ability of said candidate compound to interact with said TIAP polypeptide, wherein a candidate compound able to interact with said TIAP polypeptide is identified as a compound that modulates TIAP biological activity.

20 6. The method of claim 5, wherein said TIAP polypeptide has 85% sequence identity to SEQ ID NO: 2.

7. The method of claim 6, wherein said TIAP polypeptide has 90% sequence identity to SEQ ID NO: 2.

8. The method of claim 7, wherein said TIAP polypeptide has the sequence of SEQ ID NO: 2.

5 9. A vector comprising a substantially pure nucleic acid molecule encoding a TIAP polypeptide, said vector being capable of directing expression of said polypeptide in a vector-containing cell.

10 10. The vector of claim 9, wherein said TIAP polypeptide has 85% sequence identity to SEQ ID NO: 2.

15 11. The vector of claim 10, wherein said TIAP polypeptide has 90% sequence identity to SEQ ID NO: 2.

 12. The vector of claim 11, wherein said TIAP polypeptide has the sequence of SEQ ID NO: 2.

 13. The vector of claim 9, wherein said vector is an adenoviral vector or a retroviral vector.

 14. A cell comprising the vector of claim 9.